NEW YORK (360Dx) – Aushon BioSystems and RDL Reference Laboratory today announced a collaboration that includes the use of Aushon's multiplexing platform.
RDL has adopted Aushon's Cira technology for the simultaneous measurement of protein biomarker panels for the early detection and measurement of disease activity in several autoimmune indications. RDL will also offer Aushon's test menu as part of its newly expanded contract research organization services, and develop its own diagnostic assays using Aushon's platform.
Financial and other terms of the deal were not disclosed.
"Our collaboration with Aushon will advance our development of diagnostics with a high degree of precision and sensitivity in assays using multiple protein measurements," RDL Laboratory Director Dmitry Karayev said in a statement. "The ability to accurately and reproducibly measure small changes in multiple proteins opens up new possibilities for diagnostics in complex disease."
Aushon is a protein biomarker discovery, development, and analysis firm.
RDL provides lab services to hospitals, reference labs and physicians in rheumatology; neurology; immunology; gastroenterology/hepatology; OB/GYN/infertility; pulmonology; and hematology.